Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
about
Long-term topical cyclosporin A therapy in Thygeson's superficial punctate keratitis: a case reportAutologous serum eye drops for dry eyeAutologous serum eye drops for dry eye syndromePunctal occlusion for dry eye syndromeTopical administration of lacritin is a novel therapy for aqueous-deficient dry eye diseaseTopical ciclosporin in the treatment of ocular surface disordersComparison of the NEI-VFQ and OSDI questionnaires in patients with Sjögren's syndrome-related dry eyeTherapeutic Strategies to Treat Dry Eye in an Aging PopulationDry eye: an inflammatory ocular diseaseThe pathophysiology, diagnosis, and treatment of dry eye diseaseReviewing primary Sjögren's syndrome: beyond the dryness - From pathophysiology to diagnosis and treatmentAutologous serum eye drops for dry eye.Treatment of primary Sjögren syndrome.Text-mining applied to autoimmune disease research: the Sjögren's syndrome knowledge base.Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial.Enhanced Tearing by Electrical Stimulation of the Anterior Ethmoid NerveKorean guidelines for the diagnosis and management of dry eye: development and validation of clinical efficacy.Long-term topical cyclosporine treatment improves tear production and reduces keratoconjunctivitis in rabbits with induced autoimmune dacryoadenitis.The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study.Neuroprotectin D1 synthesis and corneal nerve regeneration after experimental surgery and treatment with PEDF plus DHADocosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases.Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy.High-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimenAging: a predisposition to dry eyes.Dry eye disease.Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.Dry eye disease: A review of diagnostic approaches and treatmentsShort-term effects of topical cyclosporine A 0.05% (Restasis) in long-standing prosthetic eye wearers: a pilot study.Emerging treatment options for meibomian gland dysfunction.The core mechanism of dry eye disease is inflammation.Dry eye as a mucosal autoimmune disease.Punctal occlusion for dry eye syndrome.Effect of Korean Red Ginseng supplementation on dry eye syndrome in glaucoma patients - A randomized, double-blind, placebo-controlled study.Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients.Topical cyclosporine a for treatment of dry eye due to chronic mustard gas injury.Fourier-domain optical coherence tomography for monitoring the lower tear meniscus in dry eye after acupuncture treatment.The chemokine receptor CCR7 expressed by dendritic cells: a key player in corneal and ocular surface inflammation.A review on recent advances in dry eye: Pathogenesis and managementEffects of corneal nerve density on the response to treatment in dry eye disease.Efficacy of a new prescription-only medical food supplement in alleviating signs and symptoms of dry eye, with or without concomitant cyclosporine A.
P2860
Q21092925-BCAEB0F0-8335-4683-BCB2-2F36F0B0B33CQ24200233-55B11881-4606-4A17-995A-43A0C3DDC272Q24234791-7EA6EFC0-2131-4B18-95AE-6C1DE57538D1Q24235284-39FF160E-A252-4F4F-BD58-E54031596777Q24563932-CF4B7537-8BFE-4B19-AAD2-888F363C3F5CQ24670344-EE7ED711-BADC-43E8-A6F0-8E99D1A2078BQ24794134-1A0752FD-52D0-4B94-8B52-443E1DC4D6C3Q26822610-F69A3BD1-EDF4-4CD0-A461-FF8F23AAAB4AQ26852044-54D969E4-7AFA-4384-BC81-E7CED8487714Q28083825-4DDAF99E-2D3C-4FAD-82D8-A4A043020B74Q30234992-C2B8DC8F-B978-4FF5-96E4-03096BEF8D23Q30235522-840DB86A-E917-4054-A5AB-2C4FB9785D91Q30249011-F489EB0A-8B72-439C-B5F2-07D2475E6BA9Q31070967-365214D9-6070-48AF-AFE9-3E6ABE7FAE7BQ33543585-4965AABC-764A-43D0-9FF6-1FBFEE3A00F4Q33585580-B4A74B25-7B97-4F16-BDD2-767CA3C18B90Q33686673-D75DEC08-651F-4C83-BC58-E9638CD507CFQ33727906-15C55FEC-CA9D-4F93-9B55-E387EFF0808DQ33804831-687338CC-64B6-47FD-BB65-433DC2F4C22DQ33845339-59A2401E-931A-4DB0-8F71-CD5783CF1EC6Q34027672-4A99E4AD-737E-4B89-A4D0-ED6C90D44FDFQ34028408-ED38EDE7-7C4C-4EAC-8792-B9D0AEB565B3Q34076208-19639C87-2490-4907-A748-4B273AF3AAAFQ34114336-FCD96833-5EFA-4B3F-B6BF-50F884EF8981Q34123349-5E7B4CD9-76E9-446C-89DC-6C7BF9D73E34Q34206399-02DAF98F-2EF5-44BC-9083-CE148DE202EFQ34273384-AC5BC2B6-F49B-41DF-A7C7-4150938B21B2Q34325595-4CC8B69E-649E-49A8-9C20-33AECE26F776Q34371781-BF207EF1-69A3-495E-AA8F-B67B35C2C8EFQ34510429-7A11FD80-F05A-4783-BA08-46CCD8AFC6E1Q34647761-6B428FA3-FC77-4C16-8513-7BF05DCA70AEQ34682290-61B0E034-93C6-4E85-9F0F-97F0754B76FEQ34719257-7A0B03F9-73FC-4FBB-ACE9-47A96331C58AQ35030126-10B137AF-2ADD-42EA-8250-48607587E000Q35087001-C901A038-E58A-40B2-971D-C35C0707A2ADQ35144078-9E141ADB-589D-4C0A-9882-64CBB0BF562AQ35145988-3B29E150-98B4-46F9-99DB-E2FDD883CD1BQ35176597-9FC4E30E-01C1-4874-A6AF-A2446A70B5B1Q35214116-FAF1E890-A9F6-4B9B-A308-88BEA59FB7E8Q35233288-8048B9D3-6196-450E-B8A7-6D755709138C
P2860
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Two multicenter, randomized st ...... ease. CsA Phase 3 Study Group.
@en
type
label
Two multicenter, randomized st ...... ease. CsA Phase 3 Study Group.
@en
prefLabel
Two multicenter, randomized st ...... ease. CsA Phase 3 Study Group.
@en
P2093
P1433
P1476
Two multicenter, randomized st ...... ease. CsA Phase 3 Study Group.
@en
P2093
P304
P356
10.1016/S0161-6420(99)00176-1
P577
2000-04-01T00:00:00Z